Method for detecting human papillomavirus mRNA

• US 7,553,623 B2
• Filed: 01/07/2003
• Issued: 06/30/2009
• Est. Priority Date: 01/07/2002
• Status: Expired due to Fees

• Current Assignee: NorChip AS
• Original Assignee: NorChip AS
• Inventors: Karlsen, Frank
• Primary Examiner(s): Horlick; Kenneth R.
• Assistant Examiner(s): Babic; Christopher M.
• Application Number:
  US10/500,832
• Publication Number:
  US 20050118568A1
• Time in Patent Office: 2,366 Days
• Field of Search: None
• US Class Current: 435/6.14
• CPC Class Codes: C12Q 1/6886 for cancer immunoassay for cancer G01N33/574
• CPC Class Codes: C12Q 1/708 for papilloma
• CPC Class Codes: C12Q 2600/16 Primer sets for multiplex assays
• CPC Class Codes: Y10S 435/975 Kit

Abstract

An in vitro method is provided for screening human female subjects to assess their risk of developing cervical carcinoma which comprises screening the subject for expression of mRNA transcripts from the E6 and optionally the L1 gene of human papillomavirus, wherein subjects positive for expression of L1 and/or E6 mRNA are scored as being at risk of developing cervical carcinoma. Kits for carrying out such methods are also provided.

Claims

1. An in vitro method of screening human subjects to assess their risk of developing cervical carcinoma, which method comprises screening the subject for expression of mRNA transcripts of the E6 gene of HPV types 16, 18, 31, 33 and/or 45 and sorting the subject into one of two categories of risk for development of cervical carcinoma based on expression of E6 mRNA, wherein individuals positive for expression of E6 mRNA from at least one of HPV types 16, 18, 31, 33 or 45, said positive expression being the presence of more than 50 copies of said E6 mRNA per milliliter of sample or per total volume of sample tested, are scored as carrying integrated HPV and are therefore classified as high risk for development of cervical carcinoma, whereas individuals negative for expression of E6 mRNA are scored as not carrying integrated HPV and are therefore classified as no detectable risk for development of cervical carcinoma.

2. A method according to claim 1 wherein screening for E6 mRNA expression is carried out using an isothermal amplification method selected from the group consisting of Nucleic Acid Sequence Based Amplification (NASBA), transcription-mediated amplification, signal-mediated amplification of RNA and isothermal solution phase amplification.

3. A method according to claim 2 wherein screening for E6 mRNA expression is carried out using real-time NASBA.

4. A method according to claim 1 wherein the human subjects are subjects previously identified as infected with human papillomavirus DNA in cells of the cervix.

5. A method according to claim 1 wherein the human subjects are subjects having a previous diagnosis of Atypical Squamous Cells of Undetermined Significance (ASCUS), Cervical Intraepithelial Neoplasia Grade I (CIN 1) lesions or condyloma.

6. A method according to claim 1 which comprises screening for expression of mRNA transcripts of the E6 gene of at least one additional HPV type which is known to be prevalent in the geographical area or population under test.

7. A method according to claim 1 which additionally comprises screening for expression of mRNA transcripts of the E6 gene of HPV type 52 and/or HPV type 58.

8. A method according to claim 1 which comprises screening for expression of mRNA transcripts of the E6 gene of HPV types 16, 18, 31, 33 and 45.

9. A method according to claim 1, wherein the step of sorting the subject into one of two categories of risk for development of cervical carcinoma based on expression of E6 mRNA alone.